Humana Inc.’s Stock Price Plummets to 246.49 USD, Experiencing a Sharp 11.79% Decline

Humana Inc. (HUM)

246.49 USD -32.96 (-11.79%) Volume: 19.62M

Humana Inc.’s stock price stands at 246.49 USD, witnessing a significant drop of -11.79% in the latest trading session with a high trading volume of 19.62M, mirroring its year-to-date performance with a steep decrease of -46.16%.

Latest developments on Humana Inc.

Humana Inc. has been facing a tumultuous period as its stock price took a hit following a sharp decline in its Medicare Star Ratings. The insurer’s Medicare Advantage plans suffered lower ratings, leading to a plunge in its stock value. The company’s 2025 membership for its top-rated Medicare plans also slumped, further contributing to the stock’s downward movement. Despite efforts to focus on quality and affordable healthcare tailored to consumer needs, Humana’s ratings debacle has exacerbated a tough year for the new CEO. Investors are closely monitoring the situation as Humana grapples with the impact of these rating cuts on its revenue and future earnings.

Humana Inc. on Smartkarma

Analysts at Baptista Research have provided bullish coverage on Humana Inc., a leading health insurance provider, on Smartkarma. In their research reports titled “Humana Inc.: Enhanced Strategic Management of Benefit Costs and Member Acquisition Tactics! – Major Drivers” and “Humana Inc.: Impacts on Pharmacy Benefit Managers (PBMs) Resulting From IRA Changes & Other Major Drivers”, the analysts highlighted the company’s mixed first-quarter results for 2024 and adjusted expectations for the upcoming year. Humana’s operational resilience, strategic expansions, and visible growth in their primary care business were emphasized, with the company reaffirming its full-year adjusted EPS guidance and increasing its membership growth outlook.

The CEO and CFO of Humana Inc., Bruce Broussard and Susan Diamond, shared important insights during a Q&A session following the earnings call, as reported by Baptista Research on Smartkarma. The analysts noted the solid start to 2024 for Humana, with the company reaffirming its full-year adjusted earnings per share guidance and increasing its individual MA membership growth outlook. The reports provide valuable information for investors looking to understand the company’s financial performance and future prospects in the health insurance industry.

A look at Humana Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Humana Inc. has received favorable Smart Scores across the board, indicating a positive long-term outlook for the company. With a strong Value score of 4, Humana is perceived as a good investment opportunity. The company’s Dividend, Growth, Resilience, and Momentum scores all sit at a solid 3, reflecting stability and potential for future growth. As a managed health care company serving members in the United States and Puerto Rico, Humana’s diverse offerings cater to employer groups, government plans, and individuals, positioning it well for continued success in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma